The variant rs3748523 (RAD52) was found to be significantly associated with lower OS (CC vs. CG + GG: hazard ratio [HR] = 2.32; 95% CI = 1.24–4.31; p = 0.008) in lung cancer patients of later stages (stage III and stage IV) adjusted for age, sex and pack-years of smoking (Table 4). This evidence concerns the gene RAD52 and lung cancer.